Fig. 1From: Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibodySummary of the patient’s hospital stay including changes in laboratory results and treatment. Dotted lines indicate grade 3 adverse events according to the Common Terminology Criteria for Adverse Events, Version 4. AST indicates aspartate transaminase; ALT, alanine transaminase; CK-MB, creatinine kinase isoenzyme MB; CK, creatinine kinase; ULN, upper limit of normal; AE, adverse event; IPI, ipilimumab; NIVO, nivolumab; Trach, tracheostomy; IVIG, intravenous immunoglobulinBack to article page